BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sells $140,574.72 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 5,632 shares of the firm’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $24.96, for a total transaction of $140,574.72. Following the transaction, the insider now directly owns 45,860 shares in the company, valued at $1,144,665.60. This trade represents a 10.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Sarah Aebersold also recently made the following trade(s):

• On Monday, March 17th, Sarah Aebersold sold 2,695 shares of BioLife Solutions stock. The stock was sold at an average price of $25.44, for a total transaction of $68,560.80.
• On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total transaction of $27,275.00.
• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $6,484.80.

BioLife Solutions Stock Performance

Shares of NASDAQ BLFS opened at $25.06 on Friday. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12 month low of $14.84 and a 12 month high of $29.55. The company has a 50 day simple moving average of $26.43 and a two-hundred day simple moving average of $25.49. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -23.64 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The business had revenue of $22.71 million during the quarter, compared to analysts’ expectations of $21.73 million. During the same period in the previous year, the business posted ($0.21) EPS. As a group, analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. HC Wainwright lifted their price objective on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Benchmark reaffirmed a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. KeyCorp lifted their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Northland Securities lifted their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. Finally, StockNews.com upgraded shares of BioLife Solutions from a “sell” rating to a “hold” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and an average target price of $29.86.

Institutional Trading of BioLife Solutions

Several institutional investors and hedge funds have recently bought and sold shares of BLFS. Steward Partners Investment Advisory LLC purchased a new position in shares of BioLife Solutions during the 4th quarter valued at approximately $26,000. Mark Sheptoff Financial Planning LLC purchased a new position in shares of BioLife Solutions during the 3rd quarter valued at approximately $28,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of BioLife Solutions during the 4th quarter valued at approximately $31,000. Quest Partners LLC purchased a new position in shares of BioLife Solutions during the 3rd quarter valued at approximately $57,000. Finally, 1620 Investment Advisors Inc. increased its holdings in shares of BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after purchasing an additional 675 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.